Showing 1091-1100 of 8881 results for "".
Topical Treatment Considerations for Psoriasis
https://practicaldermatology.com/topics/psoriasis/topical-treatment-considerations-for-psoriasis/18845/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for treating patients with mild psoriasis. They share insights about the effect of vehicles on compliance, particularly when treating patients with scalp psoriasis.Summer AAD Highlights, Alopecia Areata Discovery
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-summer-aad-highlights-alopecia-areata-discovery/18846/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, new research that suggests emerging biologic therapies could help treat alopecia areata. Plus, updates on atopic dermatitis and eczema, hands-on education, and Kybella from the AAD Summer meeting. AndAging: The Cornerstone of Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aging-the-cornerstone-of-dermatology/18865/In this edition of Derm Insider, Joseph Jorizzo, MD, Brooke Jackson, MD, and Adam Friedman, MD sit down with host Neal Bhatia, MD to discuss the phenomenon of aging and the ubiquitous role it plays in both the scientific and clinical practice of dermatology. In particular they reflect on the evolutiEpiduo Forte Approved; Facial Aesthetics By Age
https://practicaldermatology.com/topics/practice-management/dermwiretv-epiduo-forte-approved-facial-aesthetics-by-age/18870/Galderma's non-antibiotic Epiduo Forte (Adapalene 0.3% and benzoyl peroxide 2.5%) approved for topical management of acne vulgaris. Trends reveal differences in women's facial cosmetic surgery by age. AMA and CMS offer ICD-10 help. Plus: An Update on NewDerm LIVE.Cosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.DermInsider: Coming to DermTube.com
https://practicaldermatology.com/topics/practice-management/derminsider-coming-to-dermtube-com/19077/DermInsider: A Video Discussion Series Hosted by Neal Bhatia, MD. Expert Panelists. Unfiltered. New episodes coming to DermTube.com.Patient Surveys: When and Why
https://practicaldermatology.com/topics/practice-management/patient-surveys-when-and-why/19112/Todd E. Schlesinger, MD, discusses the benefits of patient surveys and offers tips to get the most out of surveys. Sometimes negative survey responses offer value to the practice--if you use the feedback to improve. Coverage from Vegas Cosmetic Surgery 2014.Dr. Joel Schlessinger discusses the importance of clinical research in your practice
https://practicaldermatology.com/topics/practice-management/dr-joel-schlessinger-discusses-the-importance-of-clinical-research-in-your-practice/19135/With hundreds of new products, procedures and technologies becoming available every day, it is important to keep up with the changing medical world. One way to do this is through clinical research at your practice. In this video, Dr. Joel Schlessinger discusses how he began his clinical research stuAlma Lasers Dye-PL Applicator for the HarmonyXL Platform
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/alma-lasers-dye-pl-applicator-for-the-harmonyxl-platform-/19243/Dye-PL is a new pulsed light applicator from Alma Lasers that concentrates the wavelength into a narrow filter of 100 nm, providing Dye Laser results, with the safety and efficiency of light.Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improv